



FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.
P1099R1C1

Serial No.
09/863,693

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant
Arathoon

Filing Date
23 May 2001

Group
Unknown *16+2*
SR

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
<i>SR</i>	* 1	4,816,567	28.03.89	Cabilly et al.	-	-	-
<i>SR</i>	* 2	5,116,964	26.05.92	Capon et al.	-	-	-

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes No
<i>SR</i>	* 3	314,317	03.05.89	EPO	/	/	/
	* 4	WO 89/02922	06.04.89	PCT			
	* 5	WO 91/08298	13.06.91	PCT			
	* 6	WO 92/10209	25.06.92	PCT			
	* 7	WO 92/22653	23.12.92	PCT			
	* 8	WO 93/06217	01.04.93	PCT			
	* 9	WO 93/11162	10.06.93	PCT			
	*10	WO 96/27011	06.09.96	PCT			
	*11	WO 96/37621	28.11.96	PCT			

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

<i>SR</i>	*12	Barton, "Protein sequence alignment and database scanning" <u>Protein Structure Prediction</u> pps. 31-63 (1996)
	*13	Berg et al., "Bispecific Antibodies that Mediate Killing of Cells Infected with Human Immunodeficiency Virus of Any Strain" <u>Proc. Natl. Acad. Sci. USA</u> 88:4723-4727 (June 1991)
	*14	Berman et al., "Protection from Genital Herpes Simplex Virus Type 2 Infection by Vaccination with Cloned Type 1 Glycoprotein D" <u>Science</u> 227(4693):1490-1492 (March 22, 1985)
	*15	Byrn et al., "Biological Properties of a CD4 Immunoaderhin" <u>Nature</u> 344:667-670 (April 12, 1990)
	*16	Carter et al., "Engineering Subtilisin BPN' for Site-Specific Proteolysis" <u>Proteins: Struct. Funct., Genet.</u> 6:240-248 (1989)
	*17	Carter et al., "High level Escherichia coli expression and production of a bivalent humanized antibody fragment" <u>Bio/Technology</u> 10:163-167 (1992)
	*18	Carter, P. et al., "Humanization of an anti-p185 ^{HER2} antibody for human cancer therapy" <u>Proc. Natl. Acad. Sci.</u> 89:4285-4289 (1992)
	*19	Chamow et al., "A Humanized, Bispecific Immunoaderhin-Antibody That Retargets CD3 ⁺ Effectors to Kill HIV-1-Infected Cells" <u>Journal of Immunology</u> 153:4268-4280 (1994)
	*20	Chothia and Lesk, "Canonical structures for the hypervariable regions of immunoglobulins" <u>J. Mol. Biol.</u> 196(4):901-917 (1987)
	*21	Clackson et al., "Making antibody fragments using phage display libraries" <u>Nature</u> 352:624-628 (1991)
	*22	de Kruif et al., "Leucine Zipper Dimerized Bivalent and Bispecific scFv Antibodies from a Semi-synthetic Antibody Phage Display Library" <u>Journal of Biological Chemistry</u> 271(13):7630-7634 (March 29, 1996)

Examiner *[Signature]*

Date Considered
10/1/02

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1099RIC1

Serial No.

09/863,693

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Arathoon

Filing Date

23 May 2001

Group

Unknown

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

SR	*23	Dietsch et al., "Bispecific Receptor Globulins, Novel Tools for the Study of Cellular Interactions" <u>Journal of Immunological Methods</u> 162:123-132 (1993)
	*24	Ellison et al., "The nucleotide sequence of a human immunoglobulin C γ 1 gene" <u>Nucleic Acids Research</u> 10(13):4071-4079 (1982)
	*25	Ellman et al., "Biosynthetic Method for Introducing Unnatural Amino Acids Site-Specifically into Proteins" <u>Meth. Enzym.</u> 202:301-336 (1991)
	*26	Fanger et al., "Bispecific Antibodies" <u>Critical Reviews in Immunology</u> 12(3,4):101-124 (1992)
	*27	Feng et al., "Aligning Amino Acid Sequences: Comparison of Commonly Used Methods" <u>J. Mol. Evol.</u> 21:112-125 (1985)
	*28	Feng et al., "Progressive Alignment and Phylogenetic Tree Construction of Protein Sequences" <u>Methods in Enzymology</u> 183:375-387 (1990)
	*29	Feng et al., "Progressive Sequence Alignment as a Prerequisite to Correct Phylogenetic Trees" <u>J. Mol. Evol.</u> 25:351-360 (1987)
	*30	Figini et al., "In Vitro Assembly of Repertoires of Antibody Chains on the Surface of Phage by Denaturation" <u>J. Mol. Biol.</u> 239:68-78 (1994)
	*31	George et al., "Current Methods in Sequence Comparison and Analysis" <u>Macromolecular Sequencing and Synthesis</u> pps. 127-149 (1988)
	*32	Griffiths et al., "Isolation of High Affinity Human Antibodies Directly From Large Synthetic Repertoires" <u>EMBO Journal</u> 13:3245-3260 (1994)
	*33	Gruber et al., "Efficient Tumor Cell Lysis Mediated by a Bispecific Single Chain Antibody Expressed in Escherichia Coli" <u>Journal of Immunology</u> 152:5368-5374 (1994)
	*34	Hammerling et al., "Use of hybrid antibody with anti- γ G and anti-ferritin specificities in locating cell surface antigens by electron microscopy" <u>Journal of Experimental Medicine</u> 128:1461-1469 (1968)
	*35	Hawkins et al., "Selection of Phage Antibodies by Binding Affinity Mimicking Affinity Maturation" <u>J. Mol. Biol.</u> 226:889-896 (1992)
	*36	Holliger et al., "'Diabodies': Small bivalent and bispecific antibody fragments" <u>Proc. Natl. Acad. Sci. USA</u> 90:6444-6448 (Jul 1993)
	*37	Kabat et al. <u>Sequences of Proteins of Immunological Interest</u> , 5th edition, Bethesda, MD:NIH Vol. 1:688-696 (1991)
	*38	Kostelny et al., "Formation of a Bispecific Antibody by the Use of Leucine Zippers" <u>Journal of Immunology</u> 148(5):1547-1553 (1992)
	*39	Lasky et al., "DNA sequence analysis of the type-common glycoprotein-D genes of herpes simplex virus types 1 and 2" <u>DNA</u> 3(1):23-29 (1984)
	*40	Le Doussal et al., "Bispecific Monoclonal Antibody-Mediated Targeting of an Indium-111-Labeled DTPA Dimer to Primary Colorectal Tumors: Pharmacokinetics, Biodistribution, Scintigraphy and Immune Response" <u>J. Nucl. Med.</u> 34:1662-1671 (1993)
	*41	Le Doussal et al., "Bispecific-Antibody-Mediated Targeting of Radiolabeled Bivalent Haptens: Theoretical, Experimental and Clinical Results" <u>Int. J. Cancer Suppl.</u> 7:58-62 (1992)
↓	*42	Marks et al., "By-passing immunization: building high affinity human antibodies by chain shuffling" <u>Bio. Technology</u> 10:779-783 (1992)

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

SEP 10 2001

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1099R1C1

Serial No

09/863,693

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Arathoon

Filing Date

23 May 2001

Group

Unknown

1642

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

SR	*43	Marks et al., "By-passing immunization: human antibodies from V-gene libraries displayed on phage" <u>J. Mol. Biol.</u> 222:581-597 (1991)
	*44	McCafferty et al., "Phage antibodies: filamentous phage displaying antibody variable domains" <u>Nature</u> 348:552-554 (1990)
	*45	Nissim et al., "Antibody fragments from a 'single pot' phage display library as immunochemical reagents" <u>EMBO Journal</u> 13(3):692-698 (1994)
	*46	Nolan et al., "Bifunctional antibodies: concept, production and applications" <u>Biochimica et Biophysica Acta</u> 1040:1-11 (1990)
	*47	Presta et al., "Humanization of an Antibody Directed Against IgE" <u>J. Immunol.</u> 151(5):2623-2632 (September 1, 1993)
	*48	Ridgway et al., "'Knobs-into-holes' Engineering of Antibody CH3 Domains for Heavy Chain Heterodimerization" <u>Protein Engineering</u> 9(7):617-621 (1996)
	*49	Rodrigues et al., "Engineering a humanized bispecific F(ab') ₂ fragment for improved binding to T cells" <u>Int. J. Cancer</u> (Suppl.) 7:45-50 (1992)
	*50	Segal et al., "Targeting and Activation of Cytotoxic Lymphocytes" <u>Chem. Immunol.</u> 47:179-213 (1989)
	*51	Shalaby et al., "Development of Humanized Bispecific Antibodies Reactive with Cytotoxic Lymphocytes and Tumor Cells Overexpressing the HER2 Protooncogene" <u>Journal of Experimental Medicine</u> 175:217-225 (Jan 1, 1992)
	*52	Songsivilai et al., "Bispecific antibody: a tool for diagnosis and treatment of disease" <u>Clin. Exp. Immunol.</u> 79:315-321 (1990)
	*53	Stickney et al., "Bifunctional Antibody: A Binary Radiopharmaceutical Delivery System for Imaging Colorectal Carcinoma" <u>Cancer Research</u> 51:6650-6655 (1991)
	*54	Suresh et al., "Bispecific Monoclonal Antibodies from Hybrid Hybridomas" <u>Methods in Enzymology</u> 121:210-228 (1986)
	*55	Vaughan et al., "Human Antibodies With Sub-nanomolar Affinities Isolated From a Large Non-immunized Phage Display Library" <u>Nature Biotechnology</u> 14:309-314 (1996)
	*56	Waterhouse et al., "Combinatorial infection and in vivo recombination: a strategy for making large phage antibody repertoires" <u>Nucleic Acids Research</u> 21:2265-2266 (1993)
	*57	Weiner et al., "A Human Tumor Xenograft Model of Therapy with a Bispecific Monoclonal Antibody Targeting c-erbB-2 and CD16" <u>Cancer Research</u> 53:94-100 (1993)
	*58	Wells and Powers, "In vivo formation and stability of engineered disulfide bonds in subtilisin" <u>J. Biol. Chemistry</u> 261(14):6564-6570 (May 15, 1986)
	*59	Zhu et al., "Remodeling domain interfaces to enhance heterodimer formation" <u>Protein Science</u> 6(4):781-788 (Apr 1997)

Examiner

Date Considered

10/1/02

*Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.